ADVANCED SOLID TUMORS

This early-phase study tested a new drug called FAZ053, either alone or with another drug (PDR001), in 154 adults with advanced solid tumors (including triple-negative breast cancer and certain sarcomas). The main goals were to check safety, find the right dose, and see how the b…

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This study tested a new drug, BLU-222, for people with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and see if it could shrink tumors. The study was ended early, so results are limited.

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This early-stage study tested a new drug called BAT8007 in 93 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. The study was terminated early, so results may be limited.

This early-stage study tested an experimental oral drug called ATX-559 in 17 people with advanced solid tumors (like breast, colon, or endometrial cancer) that had stopped responding to standard treatments. The main goal was to find a safe dose and understand side effects. The st…

This study tested a new experimental drug (BGB-30813) alone or combined with an immunotherapy (tislelizumab) in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The tria…

This study tested a new treatment called HV-101, which uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back to fight the cancer. It was designed for adults aged 18-75 with advanced solid tumors that had come back or spread. The stud…

This early-stage study tested a new drug called VVD-130850 in 132 people with advanced solid tumors or blood cancers. The goal was to see if it is safe and how the body processes it, both alone and with an immunotherapy. The trial was terminated, so results are limited.

This early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…

This early-phase study tested an oral drug (Debio 0123) combined with carboplatin chemotherapy in 76 adults with advanced solid tumors that had worsened after prior platinum-based treatment. The goal was to find the safest dose and check for side effects and early signs of tumor …

This early-phase study tested an experimental drug (PF-07265028) alone or with another drug (sasanlimab) in 21 people with advanced solid tumors like lung, stomach, or bladder cancer. The goal was to find the safest dose and see if the drugs shrink tumors. The study was stopped e…

This study tested a new experimental drug called INCA00186, alone or combined with other immunotherapies, in people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to find a safe dose and see if it could shrink tumors. The study was termina…

This early-phase study tested a new drug called 2X-121, alone and combined with another drug (dovitinib), in 14 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find safe doses and check for side effects. The study was termin…

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This early-phase study tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed. The main goals were to check for side effects and find a safe dose for future studies. Participants received the drug as an infusion and were mo…

This study tested a new drug called ASP1570 in adults with advanced solid tumors that had spread or couldn't be removed. The drug was given alone or with other cancer treatments like pembrolizumab and chemotherapy. The main goals were to check safety, find the right dose, and see…

This early-phase study tested a new drug called INCB081776, alone or with another drug (INCMGA00012), in 83 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to check safety and find the right dose. The study was terminated early, …

This early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…